Roche Quarterly Sales Held Back by Blockbuster Eye Drug

Roche Holding's quarterly results showed a slower-than-expected recovery for its eye blockbuster drug Vabysmo. Investors are now looking to a key new drug to power future growth. The company's performance was held back by the eye drug's sluggish sales, though specific financial figures were not disclosed in the report.